Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes

Analysis of a randomized control trial comparing surgery with intensive medical treatment

SANGEETA R. KASHYAP, MD¹
DEEPAK L. BHATT, MD, MPH²
KATHY WOLSKI, MPH³
RICHARD M. WATANABE, PHD⁴
MUHAMMAD ABDUL-GHANI, MD, PHD⁵
BETH ABOOD, RN¹
CLAIRE E. POTHIER, MPH³
STACY BRETTHAUER, MD⁶
STEVEN NISSEN, MD³
MANJULA GUPTA, PHD¹
JOHN P. KIRWAN, PHD⁷
PHILIP R. SCHAUER, MD⁶

OBJECTIVE—To evaluate the effects of two bariatric procedures versus intensive medical therapy (IMT) on β-cell function and body composition.

RESEARCH DESIGN AND METHODS—A prospective, randomized, controlled trial of 60 subjects with uncontrolled type 2 diabetes (HbA₁c 9.7 ± 1%) and moderate obesity (BMI 36 ± 2 kg/m²) randomized to IMT alone, IMT plus Roux-en-Y gastric bypass, or IMT plus sleeve gastrectomy. Assessment of β-cell function (mixed meal tolerance testing) and body composition were performed at baseline and 12 and 24 months.

RESULTS—Glycemic control improved in all three groups at 24 months (N = 54), with a mean HbA₁c of 6.7 ± 1.2% for gastric bypass, 7.1 ± 0.8% for sleeve gastrectomy, and 8.4 ± 2.3% for IMT (P < 0.05 for each surgical group versus IMT). Reduction in body fat was similar for both surgery groups, with greater absolute reduction in truncal fat in gastric bypass versus sleeve gastrectomy (−16 vs. −10%, P = 0.04). Insulin sensitivity increased significantly from baseline in gastric bypass (2.7-fold; P = 0.004) and did not change in sleeve gastrectomy or IMT. β-cell function (oral disposition index) increased 5.8-fold in gastric bypass from baseline, was markedly greater than IMT (P = 0.001), and was not different between sleeve gastrectomy versus IMT (P = 0.30). At 24 months, β-cell function inversely correlated with truncal fat and prandial free fatty acid levels.

CONCLUSIONS—Bariatric surgery provides durable glycemic control compared with intensive medical therapy at 2 years. Despite similar weight loss as sleeve gastrectomy, gastric bypass uniquely restores pancreatic β-cell function and reduces truncal fat, thus reversing the core defects in diabetes.

type 2 diabetes mellitus and obesity are closely interrelated chronic conditions growing in incidence worldwide, with diabetes-related deaths projected to double between 2005 and 2030 (1). The development of both insulin resistance and insulin secretory defects is the hallmark of type 2 diabetes, resulting in progressive hyperglycemia, subsequent microvascular complications, and macrovascular complications. Although lifestyle modifications and oral hypoglycemic agents improve glycemic control, the majority of patients do not achieve the optimal glycated hemoglobin (HbA₁c) levels recommended by current guidelines (≤7.0%). The disease inexorably progresses in the majority of patients, ultimately requiring insulin replacement therapy. Most patients with type 2 diabetes are overweight or obese (BMI ≥30 kg/m²) and abdominal adiposity, particularly, is tightly linked to induction of insulin resistance, metabolic syndrome, and increased cardiovascular risk. Many hypoglycemic agents, especially insulin, exacerbate weight gain and thwart lifestyle efforts, potentially contributing to the underlying pathophysiologic disorder.

Because of the limitations to medical therapy, surgical approaches for the treatment of obesity have increased 10-fold in the past decade. Roux-en-Y gastric bypass surgery is the most commonly performed in the United States, followed closely by the sleeve gastrectomy (2). Recently, two randomized controlled trials (3,4) demonstrated improved glycemic control in patients undergoing bariatric surgery compared with intensive medical therapy, resulting in the ability to withdraw or reduce glucose-lowering medications. The rapid rate of glucose-lowering, disproportionate to degree of weight loss, suggests that bariatric surgery reverses the fundamental pathophysiological defects of type 2 diabetes. Animal studies suggest that bariatric surgery increases insulin secretion or improves enteroinsulinar responses, specifically the main incretin hormones glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) (5–7). Previous small-scale studies from matched case-control and observational studies in severely obese diabetic individuals have reported that weight loss improves insulin sensitivity, reduces hyperinsulinemia, and improves pancreatic β-cell function by
weight-independent mechanisms related to an incretin effect (8–10). However, there are no data from a randomized controlled trial examining the prolonged metabolic adaptations in conjunction with clinical efficacy outcomes after bariatric surgery relative to the effects of intensive medical therapy in moderately obese subjects with poorly controlled type 2 diabetes.

The STAMPEDE trial evaluated the efficacy and safety of intensive medical therapy (IMT) alone or intensive medical therapy combined with Roux-en-Y gastric bypass or sleeve gastrectomy to achieve a primary endpoint of glycated hemoglobin level of ≤6% (with or without medications) after 1 year of follow-up (11). The current report is a 2-year extension of a metabolic substudy of the STAMPEDE trial designed to thoroughly evaluate the effects of the three treatments on glucose regulation, pancreatic β-cell function (insulin secretion/sensitivity), and body composition in a subset of 60 subjects.

**RESEARCH DESIGN AND METHODS**

**Study design**

The STAMPEDE study rationale and design have been previously reported (3,11). The first consecutive 60 subjects randomized in the main trial, with ~20 randomized to each treatment group, were included in the substudy. STAMPEDE was a single-center study that randomized patients in a 1:1:1 ratio to intensive medical therapy alone or intensive medical therapy combined with either Roux-en-Y gastric bypass or sleeve gastrectomy to achieve a primary end point of glycohemoglobin level of ≤6% (with or without medications) after 1 year of follow-up (11). The current report is a 2-year extension of a metabolic substudy of the STAMPEDE trial designed to thoroughly evaluate the effects of the three treatments on glucose regulation, pancreatic β-cell function (insulin secretion/sensitivity), and body composition in a subset of 60 subjects.

**Metabolic studies**

The mixed meal tolerance test was performed to assess glucose tolerance and metabolic measures of insulin sensitivity and secretion in response to a physiological stimulus. The liquid mixed meal consisted of a commercial product (Boost; 8 ounces, 350 kcal, 55% carbohydrate, 25% protein, 20% fat) and was consumed over 5 min after a 12- to 14-h overnight fast in a similar manner per protocol at baseline and 12 and 24 months. Fasting blood samples were obtained for glucose, C-peptide, insulin, lipids, HbA1c, adipokines, and a complete metabolic panel. Blood was drawn every 30 min for 120 min during the mixed meal tolerance testing for determination of glucose, insulin, C-peptide, and free fatty acid responses. Additional blood was drawn at fasting and at 60 min after ingestion for determination of GLP-1 and GIP responses. Glucagon levels were determined at fasting and at 120 min. Diabetes medications were withheld for 24 h before study, including insulin administration.

**Analytic determinations**

Blood glucose was measured using the glucose oxidase method (YSI 2300 STAT Plus; YSI, Yellow Springs, OH). Plasma insulin was assayed by a double-antibody radioimmunoassay (RIA; Linco Research, St. Charles, MO). The intra-assay and interassay coefficients of variations were 2.6% and 3.0%, respectively. C-peptide was assayed using a chemiluminescence immunoassay (Lumo Prodigy, Madison, WI) scan.

Of note, the Matsuda index was performed in those subjects not using exogenous insulin. The incremental AUC for ISR (ΔISR[AUC]) and the incremental AUC for plasma glucose (ΔG
[AUC]) were calculated according to the trapezoidal rule. The incretin response during meal testing subtracted the fasting value from the meal value at 60 min.

**Statistical analysis**

This is a preplanned substudy with pre-specified analysis. However, because of the lack of published data in the literature regarding specified metabolic outcome measures at the time of trial design (2004–2005), and because of the exploratory nature of the substudy, no power calculations were performed for the substudy measures. Continuous variables with a normal distribution are reported as means and SDs. Variables with a non-normal distribution are reported as medians and interquartile ranges. Categorical variables were summarized using frequencies and were tested with the $\chi^2$ statistic or Fisher exact test (two-tailed), as appropriate. One-way ANOVA was used to analyze continuous laboratory parameters and comparisons between treatment groups were performed with either the Student $t$ test or the Wilcoxon test. Glucose and insulin measures collected during the mixed meal tolerance test were plotted graphically.

**RESULTS**

**Patients**

Sixty subjects enrolled in the substudy after randomization. At 24 months, 10% were lost to follow-up, with 17 subjects remaining in intensive medical therapy and 18 and 19 subjects remaining in the gastric bypass and sleeve gastrectomy groups, respectively. Baseline characteristics for the three study groups that were followed-up for 24 months are shown in Table 1. The subjects were middle-aged, with a predominance of females, particularly in the sleeve gastrectomy group. The average BMI was 36 kg/m$^2$ with prolonged diabetes duration with mean baseline HbA$_1c$ levels of $\sim$9%, indicating poor glycemic control despite using multiple glucose-lowering agents. Nearly half were insulin users and a majority had hypertension and hyperlipidemia.

**Glycemic and cardiovascular risk control**

Table 2 shows glycemic and lipid outcomes at 12 and 24 months. Although glycemic control improved in all three arms at 24 months as compared with baseline, the gastric bypass group had significantly greater reduction in fasting glucose and HbA$_1c$ levels compared with IMT ($P < 0.05$) (Table 2). At 24 months, the proportion of patients with HbA$_1c$ $\leq$6% attenuated in the sleeve gastrectomy group from 26% to 11% but persisted in the gastric bypass group. The percent of patients using insulin at 24 months was markedly lower in gastric bypass and sleeve gastrectomy groups as compared with IMT. Large increases in HDL cholesterol and reductions in levels of triglycerides and high-sensitivity C-reactive protein were noted in both surgery groups as compared with IMT group. Other laboratory parameters and medication usage are available in Supplementary Table 1.

Three subjects randomized to bariatric surgery required reoperation, including laparoscopy to assess nausea and vomiting, for cholecystectomy and for jejunostomy for feeding access to treat a gastric leak after sleeve gastrectomy. There were no deaths or episodes of serious hypoglycemia requiring intervention, malnutrition, or excessive weight loss among the three groups.

**Body weight, body composition, and adipokines**

Greater total body weight loss occurred after bariatric procedures compared with IMT at 12 months and was maintained at 24-month follow up. A similar reduction in body weight, BMI, and absolute change in total body fat percent was observed between the sleeve gastrectomy and gastric bypass group at 24 months. However, despite similar weight loss, the absolute reduction in percent truncal fat was greater in gastric bypass versus sleeve gastrectomy group ($-16\%$ vs. $-10\%; P = 0.04$). Leptin levels reduced markedly after surgical weight loss, especially gastric bypass, compared with IMT. Suppression of free fatty acid concentration during mixed meal testing was evident after both surgical procedures versus IMT (Supplementary Table 1).

**Mixed meal tolerance**

Figure 1 demonstrates the median glucose and C-peptide levels during the mixed meal tolerance test at baseline and 24 months. At 24 months, the shape of the glucose tolerance curve for gastric bypass normalized with a marked reduction in fasting and prandial glucose levels. Intermediate effects on prandial glucose-lowering were noted in sleeve gastrectomy and IMT showed the least change. Large reductions in fasting C-peptide levels were observed in sleeve gastrectomy and gastric bypass at 24 months but did not change in the IMT group. Postprandial C-peptide levels and insulin secretion rate at 30 and 60 min increased by more than two-fold in gastric bypass and sleeve gastrectomy, with greater increases noted with gastric bypass. The average AUC for insulin secretion rate at 24 months was significantly greater with both gastric bypass ($4.4 \pm 4$ pmol/min) and sleeve gastrectomy ($3.3 \pm 2.5$ pmol/min) than IMT ($1.7 \pm 2.4$ pmol/min; both $P < 0.01$).

**Insulin sensitivity**

Median values for the insulin sensitivity (Matsuda index) in noninsulin-using subjects increased at 24 months after gastric bypass ($N = 9$) by 2.7-fold ($3.8 \pm 1.4$; $P < 0.001$) and 1.2-fold after sleeve gastrectomy ($N = 10$; $5.8 \pm 5.3$) and did not change with IMT ($2.6 \pm 2.4$; $P = $ not significant). The absolute change in median insulin sensitivity (Matsuda index) at 24 months tended to be higher in gastric bypass compared with sleeve gastrectomy ($2.3$ [quartile 1: 0.9; quartile 3: 3.1] vs. $0.9$ [quartile 1: $-1.5$; quartile 3: 4.6$]), despite equivalent weight loss.

**Pancreatic hormonal function**

The absolute change in median values for pancreatic $\beta$-cell function (oral disposition index) at 24 months was markedly greater in gastric bypass than IMT ($0.196$ [quartile 1: 0.14; quartile 3: 0.29] vs. $0.027$ [quartile 1: $-0.011$; quartile 3: 0.074$]; $P = 0.001$) but not different between sleeve gastrectomy and medical therapy ($0.058$ [quartile Q1: $-0.009$; quartile 3: 0.416] vs. $0.027$ [quartile 1: $-0.011$; quartile 3: 0.074$]; $P = 0.30$). A median 5.8-fold (quartile 1: $-7.00$; quartile Q3: 11.29) increase in $\beta$-cell function from baseline was noted in gastric bypass, with negligible increases in sleeve gastrectomy and IMT.

The change in $\beta$-cell function over 24 months for the substudy cohort correlated with the change in percentage of trunchal fat ($r = 0.43$; $P = 0.0013$) and change in body weight ($r = 0.49$; $P < 0.001$). At 24 months, both percentage of trunchal fat ($r = -0.32$; $P = 0.02$) and prandial free fatty acid levels ($r = -0.48$; $P = 0.0003$) were inversely correlated with $\beta$-cell function. In a multivariable analysis including both factors, prandial free fatty acid levels remained significant ($P = 0.004$), whereas percentage of trunchal fat was no longer significant ($P = 0.41$).

Fasting glucagon concentrations were similar among the three groups at baseline. At 12 months, median glucagon
levels tended to be lower in gastric bypass versus IMT (46 vs. 77 pg/mL; \( P = 0.07 \)) and were reduced in sleeve gastrectomy versus IMT (38 vs. 77 pg/mL; \( P < 0.02 \)). However, at 24 months fasting glucagon levels were not different among the three groups (~60 pg/mL).

Postprandial glucagon levels reduced in all three groups at 24 months from baseline values, but postprandial glucagon levels in gastric bypass were higher (77 pg/mL) than IMT (64 pg/mL; \( P < 0.05 \)) and not different between sleeve gastrectomy (65 pg/mL) and IMT.

**Incretin responses**

Median levels of GLP-1 60 minutes after mixed meal ingestion (taking into account fasting levels) increased dramatically 24 months after gastric bypass (12.5 vs. 2 pmol/L; \( P < 0.001 \)) and sleeve gastrectomy (7.3 vs. 2.4 pmol/L; \( P < 0.01 \)) and did not change with IMT (1.5 vs. 1.4 pmol/L; \( P = \) not significant). In contrast, median levels of GIP in response to mixed meal were reduced 24 months after gastric bypass (13.5 vs. 30.7 pmol/L; \( P < 0.01 \)) and were significantly different (\( P < 0.01 \)) from sleeve gastrectomy (36.9 pmol/L) and IMT (29.7 pmol/L). Both surgical groups had an overall increase in the incremental change in median GLP-1 response to mixed meal as compared with IMT at 24 months (gastric bypass 10.0 [quartile 1: 5.2; quartile 3: 15.2] pmol/L vs. sleeve gastrectomy 4.5 [quartile 1: 2.9; quartile 3: 8.2] pmol/L; \( P = 0.007 \); vs. IMT -0.4 pmol/L [quartile 1: −1.8; quartile 3: 1.1]; \( P < 0.001 \) for both). However, a reduction in GIP response was noted in gastric bypass only at 24 months (gastric bypass, −20 [quartile 1: −44.2; quartile 3: −10.2] pmol/L vs. IMT 5.4 [quartile 1: −6.3; quartile 3: 30.4] pmol/L; \( P < 0.001 \) vs. sleeve gastrectomy 0.6 [quartile 1: −18.6; quartile 3: 33.2] pmol/L; \( P = \) NS).

**Metabolic determinants of HbA1c ≤6% at 24 months**

A multivariate logistic model of metabolic parameters that were associated with HbA1c ≤6% at 24 months in the substudy cohort demonstrated that the fold increase in the oral disposition index (\( B \)-cell function) was associated with an increased odds ratio of 1.67 (CI, 1.012–2.68; \( P = 0.036 \)) to achieve glycemic control at 24 months.

**CONCLUSIONS**—Two recent bariatric surgery studies have shown markedly improved glycemic control in surgically treated patients with obesity and type 2 diabetes compared with medical therapy (3,4). In one of those studies, the STAMPEDE trial, 1 year after randomization, patients assigned to bariatric surgery were significantly more likely to achieve a glycated hemoglobin level of 6% compared with patients treated using IMT alone (3). In the current metabolic substudy, we extended follow-up of the STAMPEDE trial patients to 2 years and sought to determine the durability of the initial results and to examine the metabolic adaptations responsible for the improved glycemic control observed with bariatric surgery. We measured a wide range of metabolic parameters at three time points, at baseline, after the original 1-year follow-up, and repeated measurements 2 years after initial randomization.

After 2 years, gastric bypass provided more durable glycemic control with little or no need for glucose-lowering agents in patients randomized to this strategy. Despite comparable weight loss compared with sleeve gastrectomy, more durable glycemic control was achieved in patients randomized to gastric bypass, with a substantially greater percentage of patients attaining the target glycated hemoglobin levels of ≤6%. Attenuation of improvement in diabetes control was noted in the sleeve gastrectomy treatment group despite persistent weight loss. Other long-term observational studies have documented greater relapse rates for glycemic control after gastric restrictive procedures such as sleeve gastrectomy, suggesting that surgical weight loss from enforced caloric restriction itself is insufficient to halt the disease (14,15). Our results extend the findings from our initial 12-month report and suggest factors beyond weight loss that are specific to intestinal bypass patients help regulate glucose levels and restore pancreatic \( B \)-cell function.

Striking metabolic changes were observed in patients randomized to bariatric surgery compared with intensive medical therapy, particularly in the gastric bypass treatment group. At baseline, all randomized patients exhibited poor pancreatic secretory function. After both 1 and 2
Table 2—Clinical changes at 12 and 24 months: glycemic and lipid control

<table>
<thead>
<tr>
<th></th>
<th>IMT (N = 17)</th>
<th>Gastric bypass (N = 18)</th>
<th>Sleeve gastrectomy (N = 19)</th>
<th>(P^*)</th>
<th>(P^†)</th>
<th>(P^‡)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (\leq 6) (12 months)</td>
<td>1/16 (6.25)</td>
<td>8/18 (44.44)</td>
<td>5/19 (26.32)</td>
<td>0.02</td>
<td>0.19</td>
<td>0.25</td>
</tr>
<tr>
<td>HbA1c (\leq 6) (24 months)</td>
<td>1/17 (5.9)</td>
<td>6/18 (33.3)</td>
<td>2/19 (10.5)</td>
<td>0.09</td>
<td>1.00</td>
<td>0.12</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>35.8 ± 2.9</td>
<td>36.1 ± 2.6</td>
<td>36.4 ± 3.2</td>
<td>0.74</td>
<td>0.57</td>
<td>0.77</td>
</tr>
<tr>
<td>12 months</td>
<td>35.3 ± 3.3</td>
<td>26.7 ± 2.5</td>
<td>27.6 ± 2.3</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.27</td>
</tr>
<tr>
<td>24 months</td>
<td>35.6 ± 3.1</td>
<td>27.4 ± 2.9</td>
<td>28.2 ± 3.1</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.46</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-0.2 ± 1.41</td>
<td>-8.7 ± 3.13</td>
<td>-8.2 ± 3.01</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.66</td>
</tr>
<tr>
<td>Total body fat (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>42.2 ± 4.5</td>
<td>41.1 ± 4.7</td>
<td>46.1 ± 4.9</td>
<td>0.48</td>
<td>0.02</td>
<td>0.003</td>
</tr>
<tr>
<td>12 months</td>
<td>42.0 ± 6.7</td>
<td>27.0 ± 8.5</td>
<td>36.0 ± 6.3</td>
<td>&lt;0.001</td>
<td>0.01</td>
<td>0.001</td>
</tr>
<tr>
<td>24 months</td>
<td>43.3 ± 5.2</td>
<td>30.5 ± 8.5</td>
<td>38.4 ± 6.1</td>
<td>&lt;0.001</td>
<td>0.01</td>
<td>0.003</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>1.1 ± 1.7</td>
<td>-10.6 ± 6.6</td>
<td>-7.7 ± 3.5</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.11</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>24.9 (15.6–30.8)</td>
<td>24.0 (15.1–31.0)</td>
<td>29.6 (21.4–49.5)</td>
<td>0.93</td>
<td>0.18</td>
<td>0.10</td>
</tr>
<tr>
<td>12 months</td>
<td>24.9 (16.2–33.4)</td>
<td>4.9 (3.1–12.8)</td>
<td>10.4 (7.6–21.5)</td>
<td>&lt;0.001</td>
<td>0.003</td>
<td>0.02</td>
</tr>
<tr>
<td>24 months</td>
<td>29.3 (21.2–37.8)</td>
<td>7.2 (3.1–15.3)</td>
<td>19.1 (11.2–26.8)</td>
<td>&lt;0.001</td>
<td>0.006</td>
<td>0.01</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>4.7 (1.9–10.0)</td>
<td>-11.2 (–22.3 to –8.8)</td>
<td>-16.2 (–21.1 to –4.6)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.99</td>
</tr>
</tbody>
</table>

Unless otherwise specified, data are expressed as mean ± SD. IQR, interquartile range. \(*P\) for IMT vs. gastric bypass; \(P^†\) for IMT vs. sleeve gastrectomy; \(P^‡\) for gastric bypass vs. sleeve gastrectomy; \(P^\|$ values were generated using the Wilcoxon test; otherwise, the Student \(t\) test was used.
years of follow-up, gastric bypass patients achieved near-normal glucose tolerance after a physiological liquid mixed meal. These effects were associated with a remarkable 5.8-fold increase in overall pancreatic β-cell function. In gastric bypass patients, both insulin sensitivity and secretion components increased but, despite comparable weight loss in sleeve gastrectomy, insulin sensitivity was only partially restored and pancreatic β-cell function did not improve. Both bariatric surgery procedures stimulated incretins with markedly increased postprandial GLP-1 levels as noted in previous observational studies in obese patients with type 2 diabetes (8,9,16). However, divergence in postprandial GIP levels were noted, with a reduction seen only in gastric bypass that may be related to anatomical exclusion of the duodenum (which produces GIP) or may be reflective of improved GIP action that is noted to be defective in type 2 diabetes (17).

The metabolic changes observed in these bariatric surgical patients are markedly different from previous studies performed in medically treated patients with type 2 diabetes and highlight the clinical value of improving β-cell function to achieve glycemic control. The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that pancreatic β-cell function continues to deteriorate over time despite diet, exercise, and administration of hypoglycemic agents (18). In UKPDS, the natural history of type 2 diabetes was characterized by an average increase in glycated hemoglobin level of 1% over 2 years despite the use of medications. In patients with well-controlled diabetes prescribed a single oral hypoglycemic agent, the mean time of deterioration of glycemic control was 33–60 months (19). For patients using metformin and additionally prescribed a sulfonylurea, median HbA1c levels deteriorated as early as 6 months at a rate similar to that observed with metformin alone (20). These findings suggest that with continuing decline in β-cell function, single or even multiple agents are no longer sufficient to control blood glucose levels, which is why many patients ultimately require insulin therapy. For those who initiate insulin therapy, less than half achieve a desired HbA1c of ≤7% (21).

Although weight loss associated with hypocaloric diet has been shown to reduce insulin resistance, reduce hyperinsulinemia, and improve β-cell function (22–24), both bariatric surgery procedures displayed much larger postprandial insulinotropic

Figure 1—Glucose (A) and C-peptide (B) during the mixed meal tolerance test performed at time of randomization (baseline) and at 24 months after randomization for IMT, sleeve gastrectomy, and gastric bypass. Mixed meal consisted of Boost (8 ounces) with 30-min interval blood sampling for glucose and C-peptide values. Data are shown in median values. RYGB, Roux-en-Y gastric bypass.
effects compared with IMT. Greater insulin secretory effects of gastric bypass coupled with a nearly three-fold improvement in insulin sensitivity likely account for complete normalization of postprandial glucose tolerance seen uniquely with gastric bypass patients. Lack of suppression of glucagon is known to contribute to postprandial hyperglycemia in diabetes (25) and, contrary to our expectation, bariatric surgery did not restore this defect. A slight increase in postprandial glucagon level was noted in gastric bypass, a finding consistent with a previous study (26).

Massive weight loss and reduction of adipose tissue mass clearly contribute to the major improvements in insulin sensitivity and cardiovascular risk profile observed after bariatric surgery. However, the marked improvements in insulin sensitivity and glycemic control observed in the gastric bypass group suggest factors specifically linked to the presence of abdominal (truncal) fat. Ec- topic abdominal fat presence has long been recognized to induce insulin resistance, subclinical inflammation, and cardiovas- cular risk specific to type 2 diabetes (27,28). Previous studies also have demonstrated greater improvements in insulin sensitivity with intestinal bypass procedures (i.e., gastric bypass and biliopancreatic diversion) compared with BMI-matched nonsurgical patients, presumably because these procedures produce greater nutrient and fat malabo- sorption (29,30). In the current study, adipogenic inflammation was signifi- cantly reduced after both bariatric proce- dures, especially gastric bypass, mediated by factors such as free fatty acids, leptin, and C-reactive protein, which impair glu- cose uptake by insulin-dependent tissues (muscle and liver).

Although modest improvement in glycemic control, glucose metabolism, and clinical parameters were noted with IMT in our trial, more vigorous and behavioral/lifestyle modification strategies as used in the Look AHEAD trial (31) that aggressively target weight loss are clearly needed. Future randomized control trials are needed to compare such strategies results with bariatric sur- gery. However, maintaining weight loss in patients with diabetes who require insulin and other hypoglycemic agents is difficult in the “real world” clinical setting because conventional drug therapy generally re- sults in weight gain. In addition, fear of hypoglycemia and patient burdens related to administration of multiple drugs for diabetes and cardiovascular risk control present significant barriers to imple- menting and adhering to IMT.

A limitation of this study is the val- idity of the incretin hormone responses that were obtained after the assigned interventions. Concentrations of GLP-1 and GIP were obtained at fasting and at 60 min after meal ingestion, and this likely underestimates the incretin surge that normally occurs rapidly (within 15 min) after meal ingestion. Nevertheless, large incremental changes in prandial GLP-1 levels and corresponding C-peptide levels were noted 2 years after both bariatric procedure types that were not observed with IMT. Further studies are warranted to thoroughly investigate the long-term effects of bariatric surgery on incretin responses and action to modulate insulin secretion. Additionally, insulin sensitivity determined by the Matsuda index was performed only in a subset of subjects not using exogenous insulin at baseline and followed trends similar to the whole co- hor because insulin administration was withheld 24 h before meal testing.

In summary, bariatric surgery induces powerful metabolic effects in moderately obese patients with advanced type 2 diabetes inadequately controlled with currently avail- able drug therapy. Bariatric surgery, partic- ularly gastric bypass surgery, uniquely restores normal glucose tolerance and pan- creatic B-cell function, presumably by tar- geting the truncal fat that represents the core metabolic defect involved in diabetes path- genesis. Longer-term multicenter studies with safety outcomes are warranted to test the durability of these metabolic benefits.

Acknowledgments—Primary funding for the STAMPEDE trial is from Ethicon Endo-Surgery EES IIS 19900 (to P.R.S.). The American Di- abetes Association clinical translational award (1-11-26 CT) to S.R.K. provided ancillary funding for STAMPEDE. A grant from the National Institutes of Health (R01-DK089547) to S.R.K., P.R.S., and J.P.K. was provided.

S.R.K. obtained research grants from Ethi- con Endo-Surgery, National Institutes of Health, and American Diabetes Association. D.L.B. is a member of the Advisory Board for Medscape Cardiology, is on the Board of Di- rectors for Boston VA Research Institute and Society of Chest Pain Centers, is the Chair of American Heart Association Get With The Guidelines Science Subcommittee, received honoraria from American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today In- tervention), and WebMD (CME steering committees), is the Senior Associate Editor of Journal of Invasive Cardiology, received re- search grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Med- tronic, Sanofi Aventis, The Medicines Com- pany, and FlowCo, and performed unfunded research for Plxx Pharma and Takeda. D.L.B. receives honoraria from Ethicon Endo-Surgery as scientific advisory board member, consul- tant, and speaker, and has received honoraria from Covidiem for speaking. J.P.K. receives grant funding from National Institutes of Health, Nestle Inc., and ScottCare. P.R.S. obtained research grants from Ethicon Endo- surgery, National Institutes of Health, and Bard-Daval, received educational grants from Stryker Endoscopy, Gore, Baxter, Covidiem, and Allergan, and received honoraria from Ethicon Endo-surgery as scientific advisory board member, consultant, and speaker. P.R.S. has been a consultant/advisory board mem- ber for RemedyMD, StrykerEndoscopy, Bard- Davol, Gore, Barosense, Surgiquest, and Carefusion. S.N. has consulted with Orexigen and Vivus. S.R.K., P.R.S., and the Cleveland Clinic Coordinating Center for Clinical Re- search had full and independent access to all of the data in the study. The sponsor partici- pated in discussions regarding study design and protocol development and provided log- gistical support during the trial. The database, statistical analysis, and monitoring were all performed by the Cleveland Clinic Co- ordinating Center for Clinical Research. The manuscript was prepared by the correspond- ing author and modified after consultation with co-authors. The sponsor was permitted to review the manuscript and suggest changes, but the final decision on content and sub- mission was exclusively retained by the aca- demic authors. J. Michael Henderson, MD (Chair), James B. Young, MD, and Venu Me- non, MD, Cleveland Clinic, Cleveland, Ohio, are members of the Data and Safety Monitor- ing Board. No other potential conflicts of in- terest relevant to this article were reported.

S.R.K. was responsible for study concept and design, acquired data, provided adminis- trative technical or material support, per- formed study supervision, analyzed and interpreted data, drafted the manuscript, and obtained funding. D.L.B. was responsible for study concept and design and analysis, intepreted data, critically revised the manu- script for important intellectual content, provided administrative technical or material support, performed study supervision, and drafted the manuscript. K.W. analyzed and interpreted data, performed statistical analy- sis, and drafted the manuscript. R.M.W. ana- lyzed and interpreted data. M.A.-G. analyzed and interpreted data. B.A. was responsible for subject recruitment and for carrying out the mixed meal testing and DXA scan procedures. C.E.P. was responsible for study concept and design, drafted the manuscript, and provided
Metabolic effect of bariatric surgery for diabetes

administrative technical or material support. S.B. was responsible for study concept and design. S.N. was responsible for study concept and design, analyzed and interpreted data, and critically revised manuscript for important intellectual content. M.G. acquired data. J.P.K. analyzed and interpreted data and critically revised the manuscript for important intellectual content. P.R.S. was responsible for study concept and design, acquired data, analyzed and interpreted data, critically revised the manuscript for important intellectual content, obtained funding, provided administrative technical or material support, and performed study supervision. S.R.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This work was presented as a late-breaking poster at the at the American Diabetes Association Scientific Sessions, Philadelphia, Pennsylvania, 8–12 June 2012.

The authors are grateful to the skilled nursing care provided by Sharon O’Keefe and to Chytaine Hall, both affiliated with the Endocrinology Institute at Cleveland Clinic, for performing the metabolic studies. The authors appreciate the skilled technical expertise of Sarah Neal (Lerner Institute, Cleveland Clinic) and the laboratory staff of Preventive Research Laboratory, a core reference laboratory under the guidance of Stanley Hazen, MD, PhD (Heart and Vascular Institute and Lerner Institute, Cleveland Clinic), for performing all gut and adipose cytokines. The authors thank Rose Lounsbury, BS, Clinical Endocrinology Laboratory (Endocrinology Institute, Cleveland Clinic), for performing the assays related to fatty acids and glucagon.

References
27. Azrad M, Gower BA, Hunter GR, Nagy TR. Intra-abdominal adipose tissue is independently associated with sex-hormone binding globulin in premenopausal women. Obesity (Silver Spring) 2012;20:1012–1015